Cancer Research · 2015 · 263 citations · 40 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyCancer ImmunotherapyImmune Checkpoint InhibitorsImmune Checkpoint RegulationNatural Killer Cell BiologyNatural Killer Cell RegulationRegulatory T CellsAntibody-dependent Cell-mediated CytotoxicityAntibody-dependent Cellular CytotoxicityCetuximab TherapyCtla-4-mediated RegulationImmunosuppressive FunctionImmunosuppressive MicroenvironmentPeripheral Regulatory T CellsTumor Microenvironment Effects
The EGFR-targeted antibody cetuximab is effective against head and neck cancer (HNSCC), but in only 15% to 20% of patients, and the variability and extent of cetuximab-mediated cellular immunity is not fully understood. We hypothesized that regulatory T cells (Treg) may exert a functional and clinical impact on antitumor immunity in cetuximab-treated individuals. The frequency, immunosuppressive phenotype, and activation status of Treg and natural killer (NK) cells were analyzed in the circulation and tumor microenvironment of cetuximab-treated patients with HNSCC enrolled in a novel neoadjuvant, single-agent cetuximab clinical trial. Notably, cetuximab treatment increased the frequency of CD4(+)FOXP3(+) intratumoral Treg expressing CTLA-4, CD39, and TGFβ. These Treg suppressed cetuximab-mediated antibody-dependent cellular cytotoxicity (ADCC) and their presence correlated with poor clinical outcome in two prospective clinical trial cohorts. Cetuximab expanded CTLA-4(+)FOXP3(+) Treg in vitro, in part, by inducing dendritic cell maturation, in combination with TGFβ and T-cell receptor triggering. Importantly, cetuximab-activated NK cells selectively eliminated intratumoral Treg but preserved effector T cells. In ex vivo assays, ipilimumab targeted CTLA-4(+) Treg and restored cytolytic functions of NK cells mediating ADCC. Taken together, our results argue that differences in Treg-mediated suppression contribute to the clinical response to cetuximab treatment, suggesting its improvement by adding ipilimumab or other strategies of Treg ablation to promote antitumor immunity.
40
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
James A. Bonner, Paul M. Harari, J. Giralt et al. · New England Journal of Medicine · 2006 · 5.1K citations · Full text
CTLA-4 Control over Foxp3 <sup>+</sup> Regulatory T Cell Function
Kajsa Wing, Yasushi Onishi, Paz Prieto-Martin et al. · Science · 2008 · 2.9K citations
François Ghiringhelli, Cédric Menard, Magali Terme et al. · The Journal of Experimental Medicine · 2005 · 919 citations · Full text
Life Sciences, Immunology, Oncology +17